Literature DB >> 7115838

Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders.

K Kasa, S Otsuki, M Yamamoto, M Sato, H Kuroda, N Ogawa.   

Abstract

gamma-Aminobutyric acid (GABA) and homovanillic acid (HVA) levels were determined in the lumbar cerebrospinal fluid (CSF) of hospitalized patients suffering from depression and in a control group. Both mean CSF GABA and HVA levels in the patients with depression were significantly lower than those of the control group (p less than 0.05, p less than 0.01, respectively). No positive correlation was found between the changes in CSF GABA and HVA levels in the patients with depression. The Hamilton Rating score in these depressed patients, age, and sex showed no correlation to CSF GABA levels. It is suggested that decreased activity in the central GABAergic and dopaminergic system may be involved in the pathogenesis of depression.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7115838

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  30 in total

1.  Developmental influence of the serotonin transporter on the expression of npas4 and GABAergic markers: modulation by antidepressant treatment.

Authors:  Gianluigi Guidotti; Francesca Calabrese; Francesca Auletta; Jocelien Olivier; Giorgio Racagni; Judith Homberg; Marco A Riva
Journal:  Neuropsychopharmacology       Date:  2011-10-19       Impact factor: 7.853

2.  Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid.

Authors:  J John Mann; Maria A Oquendo; Kalycia Trishana Watson; Maura Boldrini; Kevin M Malone; Steven P Ellis; Gregory Sullivan; Thomas B Cooper; Shan Xie; Dianne Currier
Journal:  Depress Anxiety       Date:  2014-05-27       Impact factor: 6.505

Review 3.  Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives.

Authors:  Corey Fee; Mounira Banasr; Etienne Sibille
Journal:  Biol Psychiatry       Date:  2017-06-08       Impact factor: 13.382

Review 4.  Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders.

Authors:  Thomas Prévot; Etienne Sibille
Journal:  Mol Psychiatry       Date:  2020-04-28       Impact factor: 15.992

5.  Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder.

Authors:  Rebecca B Price; Dikoma C Shungu; Xiangling Mao; Paul Nestadt; Chris Kelly; Katherine A Collins; James W Murrough; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2008-12-05       Impact factor: 13.382

6.  Mind-Body Practices and the Adolescent Brain: Clinical Neuroimaging Studies.

Authors:  Anup Sharma; Andrew B Newberg
Journal:  Adolesc Psychiatry (Hilversum)       Date:  2015

Review 7.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Fluoxetine partly exerts its actions through GABA: a neurochemical evidence.

Authors:  M Zafer Gören; Esra Küçükibrahimoglu; Kemal Berkman; Berna Terzioglu
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

9.  Vigabatrin and depression.

Authors:  H A Ring; R Crellin; S Kirker; E H Reynolds
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-08       Impact factor: 10.154

Review 10.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.